These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 11428914)
1. Preventing drug access to targets: cell surface permeability barriers and active efflux in bacteria. Nikaido H Semin Cell Dev Biol; 2001 Jun; 12(3):215-23. PubMed ID: 11428914 [TBL] [Abstract][Full Text] [Related]
2. [The role of cell wall organization and active efflux pump systems in multidrug resistance of bacteria]. Hasdemir U Mikrobiyol Bul; 2007 Apr; 41(2):309-27. PubMed ID: 17682720 [TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance mechanisms: drug efflux across two membranes. Zgurskaya HI; Nikaido H Mol Microbiol; 2000 Jul; 37(2):219-25. PubMed ID: 10931319 [TBL] [Abstract][Full Text] [Related]
4. Understanding efflux in Gram-negative bacteria: opportunities for drug discovery. Schweizer HP Expert Opin Drug Discov; 2012 Jul; 7(7):633-42. PubMed ID: 22607346 [TBL] [Abstract][Full Text] [Related]
5. Multiantibiotic resistance caused by active drug extrusion in Pseudomonas aeruginosa and other gram-negative bacteria. Nakae T Microbiologia; 1997 Sep; 13(3):273-84. PubMed ID: 9353746 [TBL] [Abstract][Full Text] [Related]
7. Channel-tunnels: outer membrane components of type I secretion systems and multidrug efflux pumps of Gram-negative bacteria. Andersen C Rev Physiol Biochem Pharmacol; 2003; 147():122-65. PubMed ID: 12783268 [TBL] [Abstract][Full Text] [Related]
8. A model of a transmembrane drug-efflux pump from Gram-negative bacteria. Fernandez-Recio J; Walas F; Federici L; Venkatesh Pratap J; Bavro VN; Miguel RN; Mizuguchi K; Luisi B FEBS Lett; 2004 Dec; 578(1-2):5-9. PubMed ID: 15581607 [TBL] [Abstract][Full Text] [Related]
9. The bacterial outer membrane as a drug barrier. Hancock RE Trends Microbiol; 1997 Jan; 5(1):37-42. PubMed ID: 9025234 [TBL] [Abstract][Full Text] [Related]
10. [Antibiotic resistance caused by membrane impermeability and multidrug efflux systems]. Gotoh N Nihon Rinsho; 2001 Apr; 59(4):712-8. PubMed ID: 11304994 [TBL] [Abstract][Full Text] [Related]
12. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Nikaido H Science; 1994 Apr; 264(5157):382-8. PubMed ID: 8153625 [TBL] [Abstract][Full Text] [Related]
13. Molecular basis of antimicrobial resistance in non-typable Haemophilus influenzae. Sánchez L; Leranoz S; Puig M; Lorén JG; Nikaido H; Viñas M Microbiologia; 1997 Sep; 13(3):309-14. PubMed ID: 9353749 [TBL] [Abstract][Full Text] [Related]
14. Inhibitors of efflux pumps in Gram-negative bacteria. Pagès JM; Masi M; Barbe J Trends Mol Med; 2005 Aug; 11(8):382-9. PubMed ID: 15996519 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria. Lomovskaya O; Watkins W J Mol Microbiol Biotechnol; 2001 Apr; 3(2):225-36. PubMed ID: 11321578 [TBL] [Abstract][Full Text] [Related]
17. [Bacterial resistance to arsenic compounds]. Cervantes C Rev Latinoam Microbiol; 1995; 37(4):387-95. PubMed ID: 8900573 [TBL] [Abstract][Full Text] [Related]
18. Bacterial antibiotic efflux systems of medical importance. Köhler T; Pechère JC; Plésiat P Cell Mol Life Sci; 1999 Nov; 56(9-10):771-8. PubMed ID: 11212337 [TBL] [Abstract][Full Text] [Related]
19. Strategies for bypassing the membrane barrier in multidrug resistant Gram-negative bacteria. Bolla JM; Alibert-Franco S; Handzlik J; Chevalier J; Mahamoud A; Boyer G; Kieć-Kononowicz K; Pagès JM FEBS Lett; 2011 Jun; 585(11):1682-90. PubMed ID: 21549704 [TBL] [Abstract][Full Text] [Related]